GV has contributed to a $92m series B for Tenaya, three years after it was spun out of Gladstone Institutes and University of Texas Southwestern Medical Center.

Praktikertjänst-backed Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.

Icosavax has launched with $51m in series A funding from Sanofi Ventures and others to move a vaccine for respiratory syncytial virus into a phase 1b trial.

Livzon Pharmaceutical Group has been identified as an investor by Elicio Therapeutics, which just completed a series B round that takes its total financing to $63m.

CareStack's latest round attracted Delta Dental of California and will be used to extend the dental management software provider's customer base.

Icosavax has launched out of University of Washington with $51m in series A funding to move a vaccine for respiratory syncytial virus into a phase 1b trial.

Frequency, a regenerative medicine developer based on MIT and Harvard research, priced shares at the bottom of its range to raise $84m in its IPO.

The Alexandria Real Estate Equities-backed regenerative medicine developer floated at the bottom of its range while cutting the number of shares.

The genome mapping system developer took its total funding past the $100m mark in a round led by Hitachi High-Technologies.

Samsung, OCI, Regeneron, Handok, Johnson & Johnson and existing investor Novartis all took part in the cell therapy developer's latest round.